|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOLGA2 |
Gene summary for GOLGA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOLGA2 | Gene ID | 2801 |
| Gene name | golgin A2 | |
| Gene Alias | GM130 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q08379 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2801 | GOLGA2 | S029 | Human | Liver | HCC | 1.31e-18 | 1.27e+00 | 0.2581 |
| 2801 | GOLGA2 | C04 | Human | Oral cavity | OSCC | 9.71e-09 | 5.49e-01 | 0.2633 |
| 2801 | GOLGA2 | C21 | Human | Oral cavity | OSCC | 5.28e-27 | 9.86e-01 | 0.2678 |
| 2801 | GOLGA2 | C30 | Human | Oral cavity | OSCC | 2.13e-44 | 1.87e+00 | 0.3055 |
| 2801 | GOLGA2 | C43 | Human | Oral cavity | OSCC | 7.13e-03 | 1.45e-01 | 0.1704 |
| 2801 | GOLGA2 | C46 | Human | Oral cavity | OSCC | 1.95e-06 | 3.02e-01 | 0.1673 |
| 2801 | GOLGA2 | C51 | Human | Oral cavity | OSCC | 7.83e-16 | 9.45e-01 | 0.2674 |
| 2801 | GOLGA2 | C57 | Human | Oral cavity | OSCC | 3.07e-13 | 5.82e-01 | 0.1679 |
| 2801 | GOLGA2 | C06 | Human | Oral cavity | OSCC | 4.55e-10 | 1.45e+00 | 0.2699 |
| 2801 | GOLGA2 | C08 | Human | Oral cavity | OSCC | 1.74e-13 | 4.00e-01 | 0.1919 |
| 2801 | GOLGA2 | C09 | Human | Oral cavity | OSCC | 3.36e-13 | 5.07e-01 | 0.1431 |
| 2801 | GOLGA2 | LN22 | Human | Oral cavity | OSCC | 4.50e-04 | 8.79e-01 | 0.1733 |
| 2801 | GOLGA2 | LN38 | Human | Oral cavity | OSCC | 1.58e-02 | 9.13e-01 | 0.168 |
| 2801 | GOLGA2 | LN46 | Human | Oral cavity | OSCC | 1.30e-03 | 2.32e-01 | 0.1666 |
| 2801 | GOLGA2 | LP15 | Human | Oral cavity | LP | 1.56e-03 | 7.85e-01 | 0.2174 |
| 2801 | GOLGA2 | SYSMH1 | Human | Oral cavity | OSCC | 2.59e-37 | 8.43e-01 | 0.1127 |
| 2801 | GOLGA2 | SYSMH2 | Human | Oral cavity | OSCC | 7.27e-27 | 7.12e-01 | 0.2326 |
| 2801 | GOLGA2 | SYSMH3 | Human | Oral cavity | OSCC | 1.68e-36 | 7.66e-01 | 0.2442 |
| 2801 | GOLGA2 | SYSMH5 | Human | Oral cavity | OSCC | 8.00e-07 | 2.65e-01 | 0.0647 |
| 2801 | GOLGA2 | SYSMH6 | Human | Oral cavity | OSCC | 6.42e-13 | 4.22e-01 | 0.1275 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819317 | Esophagus | HGIN | Golgi vesicle transport | 83/2587 | 296/18723 | 8.59e-11 | 8.89e-09 | 83 |
| GO:000989520 | Esophagus | HGIN | negative regulation of catabolic process | 87/2587 | 320/18723 | 1.74e-10 | 1.68e-08 | 87 |
| GO:003133026 | Esophagus | HGIN | negative regulation of cellular catabolic process | 74/2587 | 262/18723 | 6.27e-10 | 5.30e-08 | 74 |
| GO:001050616 | Esophagus | HGIN | regulation of autophagy | 84/2587 | 317/18723 | 1.39e-09 | 1.08e-07 | 84 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:00068889 | Esophagus | HGIN | endoplasmic reticulum to Golgi vesicle-mediated transport | 40/2587 | 130/18723 | 4.67e-07 | 2.07e-05 | 40 |
| GO:19030089 | Esophagus | HGIN | organelle disassembly | 36/2587 | 114/18723 | 8.60e-07 | 3.58e-05 | 36 |
| GO:00105076 | Esophagus | HGIN | negative regulation of autophagy | 27/2587 | 85/18723 | 1.72e-05 | 4.71e-04 | 27 |
| GO:005109825 | Esophagus | HGIN | regulation of binding | 78/2587 | 363/18723 | 3.73e-05 | 9.30e-04 | 78 |
| GO:005125826 | Esophagus | HGIN | protein polymerization | 66/2587 | 297/18723 | 4.96e-05 | 1.19e-03 | 66 |
| GO:00070527 | Esophagus | HGIN | mitotic spindle organization | 31/2587 | 120/18723 | 3.35e-04 | 5.50e-03 | 31 |
| GO:01400146 | Esophagus | HGIN | mitotic nuclear division | 61/2587 | 287/18723 | 3.38e-04 | 5.55e-03 | 61 |
| GO:19028507 | Esophagus | HGIN | microtubule cytoskeleton organization involved in mitosis | 36/2587 | 147/18723 | 3.61e-04 | 5.68e-03 | 36 |
| GO:00070518 | Esophagus | HGIN | spindle organization | 42/2587 | 184/18723 | 6.07e-04 | 8.49e-03 | 42 |
| GO:00903077 | Esophagus | HGIN | mitotic spindle assembly | 18/2587 | 65/18723 | 2.46e-03 | 2.45e-02 | 18 |
| GO:003209110 | Esophagus | HGIN | negative regulation of protein binding | 23/2587 | 94/18723 | 3.92e-03 | 3.54e-02 | 23 |
| GO:005110020 | Esophagus | HGIN | negative regulation of binding | 35/2587 | 162/18723 | 4.32e-03 | 3.84e-02 | 35 |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOLGA2 | SNV | Missense_Mutation | c.50C>T | p.Thr17Ile | p.T17I | Q08379 | protein_coding | deleterious(0) | possibly_damaging(0.602) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| GOLGA2 | SNV | Missense_Mutation | c.1205G>T | p.Gly402Val | p.G402V | Q08379 | protein_coding | tolerated(0.11) | benign(0.053) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| GOLGA2 | SNV | Missense_Mutation | novel | c.837G>C | p.Gln279His | p.Q279H | Q08379 | protein_coding | deleterious(0.05) | benign(0.363) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| GOLGA2 | SNV | Missense_Mutation | novel | c.570N>T | p.Gln190His | p.Q190H | Q08379 | protein_coding | deleterious(0.04) | benign(0.243) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GOLGA2 | SNV | Missense_Mutation | c.1145T>G | p.Val382Gly | p.V382G | Q08379 | protein_coding | deleterious(0) | benign(0.058) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| GOLGA2 | SNV | Missense_Mutation | c.1145N>G | p.Val382Gly | p.V382G | Q08379 | protein_coding | deleterious(0) | benign(0.058) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GOLGA2 | SNV | Missense_Mutation | novel | c.2533N>A | p.Glu845Lys | p.E845K | Q08379 | protein_coding | tolerated(0.05) | benign(0.259) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| GOLGA2 | SNV | Missense_Mutation | c.2659N>A | p.Glu887Lys | p.E887K | Q08379 | protein_coding | tolerated(0.08) | benign(0.13) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| GOLGA2 | SNV | Missense_Mutation | novel | c.97C>G | p.Gln33Glu | p.Q33E | Q08379 | protein_coding | tolerated(0.09) | probably_damaging(0.994) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GOLGA2 | SNV | Missense_Mutation | c.2290C>T | p.Arg764Cys | p.R764C | Q08379 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |